CONCLUSION: HF-rTMS appears to provide consistent cognitive benefits in Alzheimer’s disease and VCI, whereas its efficacy in other neuropsychiatric disorders remains uncertain. Given the low certainty of evidence and substantial heterogeneity, findings should be interpreted with caution. Future large-scale, multicenter randomized controlled trials with standardized protocols are needed to confirm efficacy and support clinical implementation.
